{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:05:45Z","timestamp":1786997145950,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.steroids.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T10:31:21Z","timestamp":1403001081000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators"],"prefix":"10.1016","volume":"90","author":[{"given":"V.","family":"Craig Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"McDaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadeke","family":"Agboke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Y.","family":"Maximov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/endo-63-3-295","article-title":"A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol","volume":"63","author":"Lerner","year":"1958","journal-title":"Endocrinology"},{"issue":"178","key":"10.1016\/j.steroids.2014.06.009_b0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jama.1961.03040410001001","article-title":"Induction of ovulation with MRL\/41. Preliminary report","volume":"14","author":"Greenblatt","year":"1961","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.009_b0015","series-title":"Non-steroidal antioestrogens: molecular pharmacology and antitumour activity","first-page":"1","article-title":"The first nonsteroidal antioestrogen \u2013 MER25","author":"Lerner","year":"1981"},{"key":"10.1016\/j.steroids.2014.06.009_b0020","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/S0021-9258(20)81321-0","article-title":"Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29","volume":"235","author":"Avigan","year":"1960","journal-title":"J Biol Chem"},{"issue":"181","key":"10.1016\/j.steroids.2014.06.009_b0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jama.1962.03050300059020a","article-title":"Cataracts in patients treated with triparanol","volume":"28","author":"Laughlin","year":"1962","journal-title":"JAMA"},{"issue":"9869","key":"10.1016\/j.steroids.2014.06.009_b0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.009_b0035","first-page":"39","article-title":"Clomiphene Citrate (NSC-35770) in disseminated mammary carcinoma","volume":"43","author":"Herbst","year":"1964","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0040","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/jm00320a002","article-title":"Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and their derivatives","volume":"9","author":"Lednicer","year":"1966","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/1097-0142(197610)38:4<1535::AID-CNCR2820380415>3.0.CO;2-M","article-title":"Nafoxidine \u2013 an antiestrogen for the treatment of breast cancer","volume":"38","author":"Legha","year":"1976","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.steroids.2014.06.009_b0050","first-page":"3461","article-title":"Report: adjuvant chemotherapy of breast cancer","volume":"254","author":"Consensus development conference","year":"1985","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0055","first-page":"169","article-title":"Anti-implantation effect of 2,3-diphenylacrylophenones","volume":"5","author":"Iyer","year":"1967","journal-title":"Indian J Exp Biol"},{"issue":"8","key":"10.1016\/j.steroids.2014.06.009_b0060","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/jm00194a015","article-title":"Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt","volume":"22","author":"Jones","year":"1979","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.steroids.2014.06.009_b0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0024-3205(80)90049-1","article-title":"Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice","volume":"26","author":"Black","year":"1980","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.steroids.2014.06.009_b0070","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0024-3205(83)90935-9","article-title":"Antagonism of estrogen action with a new benzothiophene derived antiestrogen","volume":"32","author":"Black","year":"1983","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1980.tb10912.x","article-title":"Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships","volume":"71","author":"Allen","year":"1980","journal-title":"Br J Pharmacol"},{"issue":"5227","key":"10.1016\/j.steroids.2014.06.009_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/225080a0","article-title":"Role of oestrogen in spontaneous ovulation demonstrated by use of an antagonist of oestrogen, ICI 46,474","volume":"225","author":"Labhsetwar","year":"1970","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/endo-87-3-542","article-title":"Role of estrogens in ovulation: a study using the estrogen-antagonist, I.C.I. 46,474","volume":"87","author":"Labhsetwar","year":"1970","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/jrf.0.0250295","article-title":"Effects of an antioestrogen on the corpus luteum of rabbits and rats","volume":"25","author":"Labhsetwar","year":"1971","journal-title":"J Reprod Fertil"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/endo-90-4-941","article-title":"Role of estrogens in spontaneous ovulation: evidence for the positive feedback in hamsters","volume":"90","author":"Labhsetwar","year":"1972","journal-title":"Endocrinology"},{"issue":"5057","key":"10.1016\/j.steroids.2014.06.009_b0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/212087a0","article-title":"Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes","volume":"212","author":"Harper","year":"1966","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A new derivative of triphenylethylene: effect on implantation and mode of action in rats","volume":"13","author":"Harper","year":"1967","journal-title":"J Reprod Fertil"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1677\/joe.0.0370083","article-title":"Mode of action of I.C.I. 46,474 in preventing implantation in rats","volume":"37","author":"Harper","year":"1967","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01807278","article-title":"The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole","volume":"11","author":"Jordan","year":"1988","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br J Cancer"},{"issue":"5844","key":"10.1016\/j.steroids.2014.06.009_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","article-title":"Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels","volume":"1","author":"Ward","year":"1973","journal-title":"Br Med J"},{"issue":"5741","key":"10.1016\/j.steroids.2014.06.009_b0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.5741.152","article-title":"New synthetic agent for the induction of ovulation: preliminary trials in women","volume":"1","author":"Klopper","year":"1971","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2964(75)90119-X","article-title":"Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor","volume":"11","author":"Jordan","year":"1975","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2014.06.009_b0145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0022-4731(74)90388-4","article-title":"Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethyl benzanthracene (DMBA)-induced rat mammary carcinoma model","volume":"5","author":"Jordan","year":"1974","journal-title":"J Steroid Biochem"},{"issue":"6","key":"10.1016\/j.steroids.2014.06.009_b0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","article-title":"Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata","volume":"12","author":"Jordan","year":"1976","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2014.06.009_b0155","unstructured":"Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Relat Cancer 1978;(October supplement):49\u201355."},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.steroids.2014.06.009_b0165","unstructured":"Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon S, Jones S, editors. Adjuvant Therapy of Cancer II. New York: Grune & Stratton Inc; 1979. p. 19\u201326."},{"issue":"9114","key":"10.1016\/j.steroids.2014.06.009_b0170","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"issue":"9472","key":"10.1016\/j.steroids.2014.06.009_b0175","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"},{"issue":"9793","key":"10.1016\/j.steroids.2014.06.009_b0180","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/ajc.1936.217","article-title":"Hormonal pathogenesis of adenocarcinoma of the breast","volume":"27","author":"Lacassagne","year":"1936","journal-title":"Am J Cancer"},{"issue":"14","key":"10.1016\/j.steroids.2014.06.009_b0190","first-page":"4177","article-title":"Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.009_b0195","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1042\/bj0720673","article-title":"Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep","volume":"72","author":"Glascock","year":"1959","journal-title":"Biochem J"},{"key":"10.1016\/j.steroids.2014.06.009_b0200","first-page":"387","article-title":"Basic guides to the mechanism of estrogen action","volume":"18","author":"Jensen","year":"1962","journal-title":"Recent Prog Horm Res"},{"issue":"6","key":"10.1016\/j.steroids.2014.06.009_b0205","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1073\/pnas.55.6.1574","article-title":"A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization","volume":"55","author":"Toft","year":"1966","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.steroids.2014.06.009_b0210","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1073\/pnas.57.6.1740","article-title":"A receptor molecule for estrogens: studies using a cell-free system","volume":"57","author":"Toft","year":"1967","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.steroids.2014.06.009_b0215","unstructured":"McGuire WL, Carbone PP, Vollmer EP, editors. Estrogen Receptors in Human Breast Cancer, Raven Press; 1975."},{"issue":"6","key":"10.1016\/j.steroids.2014.06.009_b0220","first-page":"1980","article-title":"The estrogen receptor: a model for molecular medicine","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.009_b0225","first-page":"30","article-title":"Anti-oestrogen action in experimental breast cancer","volume":"71","author":"Jordan","year":"1980","journal-title":"Recent Results Cancer Res"},{"issue":"8449","key":"10.1016\/j.steroids.2014.06.009_b0230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(85)90338-1","article-title":"Tamoxifen and contralateral breast cancer","volume":"2","author":"Cuzick","year":"1985","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/bjc.1989.235","article-title":"A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer","volume":"60","author":"Powles","year":"1989","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0240","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.steroids.2014.06.009_b0245","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/0006-2952(85)90580-5","article-title":"Metabolism of tamoxifen and its uterotrophic activity","volume":"34","author":"Lyman","year":"1985","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.steroids.2014.06.009_b0250","first-page":"1870","article-title":"Species-specific pharmacology of antiestrogens: role of metabolism","volume":"46","author":"Jordan","year":"1987","journal-title":"Fed Proc"},{"issue":"7","key":"10.1016\/j.steroids.2014.06.009_b0255","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jnci\/83.7.492","article-title":"Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy","volume":"83","author":"Jordan","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0260","first-page":"812","article-title":"Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Res"},{"issue":"8610","key":"10.1016\/j.steroids.2014.06.009_b0265","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(88)92675-X","article-title":"Tamoxifen as risk factor for carcinoma of corpus uteri","volume":"2","author":"Hardell","year":"1988","journal-title":"Lancet"},{"issue":"8618","key":"10.1016\/j.steroids.2014.06.009_b0270","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(88)90765-9","article-title":"Tamoxifen and endometrial cancer","volume":"2","author":"Jordan","year":"1988","journal-title":"Lancet"},{"issue":"8630","key":"10.1016\/j.steroids.2014.06.009_b0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.steroids.2014.06.009_b0280","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.steroids.2014.06.009_b0285","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"10.1016\/j.steroids.2014.06.009_b0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"issue":"9336","key":"10.1016\/j.steroids.2014.06.009_b0295","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/carcin\/14.2.315","article-title":"The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat","volume":"14","author":"Williams","year":"1993","journal-title":"Carcinogenesis"},{"issue":"17","key":"10.1016\/j.steroids.2014.06.009_b0305","first-page":"3919","article-title":"Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats","volume":"53","author":"Greaves","year":"1993","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.steroids.2014.06.009_b0310","first-page":"4534","article-title":"Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats","volume":"53","author":"Hard","year":"1993","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/oxfordjournals.annonc.a059035","article-title":"What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective","volume":"6","author":"Jordan","year":"1995","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.steroids.2014.06.009_b0320","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0325","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.009_b0330","doi-asserted-by":"crossref","unstructured":"Jordan C. Tamoxifen as the first targeted long term adjuvant therapy for breast cancer. Endocr Relat Cancer 2014 Mar 21.","DOI":"10.1530\/ERC-14-0092"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.steroids.2014.06.009_b0340","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.steroids.2014.06.009_b0345","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women","volume":"115","author":"Love","year":"1991","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.steroids.2014.06.009_b0350","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"15","key":"10.1016\/j.steroids.2014.06.009_b0360","first-page":"4020","article-title":"Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model","volume":"47","author":"Gottardis","year":"1987","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0365","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0022-4731(83)90147-4","article-title":"Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor","volume":"19","author":"Jordan","year":"1983","journal-title":"J Steroid Biochem"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0370","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/endo-113-2-463","article-title":"Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018","volume":"113","author":"Jordan","year":"1983","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.steroids.2014.06.009_b0375","first-page":"3189","article-title":"Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice","volume":"50","author":"Gottardis","year":"1990","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","article-title":"Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats","volume":"93","author":"Black","year":"1994","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.steroids.2014.06.009_b0385","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.steroids.2014.06.009_b0390","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.steroids.2014.06.009_b0395","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.steroids.2014.06.009_b0400","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"issue":"5","key":"10.1016\/j.steroids.2014.06.009_b0405","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/07357908809082124","article-title":"Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations","volume":"6","author":"Jordan","year":"1988","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.009_b0410","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003495-199754010-00014","article-title":"Toremifene. a review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer","volume":"54","author":"Wiseman","year":"1997","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0415","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.steroids.2014.06.009_b0420","unstructured":"Jordan VC. A(nother) scientific strategy to prevent breast cancer in post-menopausal women by enhancing estrogen-induced apoptosis?. Menopause [ePub]."},{"issue":"4","key":"10.1016\/j.steroids.2014.06.009_b0425","first-page":"784","article-title":"In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo","volume":"48","author":"Robinson","year":"1988","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.steroids.2014.06.009_b0430","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/jm010086m","article-title":"Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens","volume":"44","author":"Miller","year":"2001","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0006-2952(83)90571-3","article-title":"Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy","volume":"32","author":"Bain","year":"1983","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.009_b0440","first-page":"1446","article-title":"Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer","volume":"43","author":"Jordan","year":"1983","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.steroids.2014.06.009_b0445","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.steroids.2014.06.009_b0450","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.009_b0455","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.009_b0460","unstructured":"Jordan VC. Repurposing failed pharmaceuticals as the first targeted medicines for the treatment and prevention of breast cancer. Hamdan Med J. in press."},{"issue":"22","key":"10.1016\/j.steroids.2014.06.009_b0465","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.steroids.2014.06.009_b0470","first-page":"4090","article-title":"Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens","volume":"49","author":"Gottardis","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.009_b0475","series-title":"Tamoxifen: pioneering medicine in breast cancer. Milestones in drug therapy","author":"Maximov","year":"2013"},{"key":"10.1016\/j.steroids.2014.06.009_b0480","series-title":"Estrogen action, selective estrogen receptor modulators and women\u2019s health: progress and promise","year":"2013"},{"key":"10.1016\/j.steroids.2014.06.009_b0485","series-title":"Comprehensive medicinal chemistry II","first-page":"103","article-title":"Case histories: raloxifene","author":"Lewis","year":"2006"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T11:26:33Z","timestamp":1649417193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14001482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":97,"alternative-id":["S0039128X14001482"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.009","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}